- Buy above: ₹2,330
- Stop Loss: ₹2,180
- Target Price: ₹2,675
- Timeframe: 2 months
Why it’s recommended: Gland Pharma is a leading injectable-focused pharmaceutical company with a strong footprint in the US, Europe, Canada, Australia, and key emerging markets. After building a solid base near the ₹1,600 mark, the stock has been in a sustained uptrend, recently hitting a fresh 52-week high. The current consolidation in the ₹2,250–2,350 range represents a healthy, temporary pause within a larger bullish cycle. Strong recent earnings, turning profitability at its European subsidiary Cenexi, and ongoing capacity expansion plans continue to bolster investor confidence.
About The Author
